05);HGF组及HGF+G-SCF组血浆中ET-1的含量显著低于PAH组(P
头颈部鳞癌占头颈部癌的90%,具有较高的死亡率,虽然治疗方法有所更新,但其生存率近年来却无明显提高。在细胞及分子水平理解肿瘤侵袭等病理学特性成为头巾外科一个重要的目标。近年来研究表明肝细胞生长因子在肿瘤细胞生长、浸润、转移过程中起重要的调节作用。近些年来,对这些生长因子及其受体的研究,无论是在基础方面,还是在临床病理学方面都取得了很大进展,为抗肿瘤治疗开辟了广阔的前景。对肝细胞生长因子的特征及其生物学特性,以及目前研究的重要进展做一综述。
原发性肝细胞肝癌(hepatocellular carcinoma,HCC)是最常见的原发性肝肿瘤,严重威胁人类健康。全世界范围内肝癌的发病率呈明显的地域性差别,以亚非地区较高,我国发病率和病死率均居前。最近的统计数据表明,肝癌的发病率居全球肿瘤的第6位,病死率居第3位[1],亚洲的肝癌患者约占全世界的80%,肝癌已成为人类恶性肿瘤疾病中致死性因素之一[2]。随着医学科学的不断进步,医学诊疗
近年来,许多研究者在体外实验或者临床试验中发现肝细胞生长因子受体对许多肿瘤的发生和发展起到了关键的作用。HGF/c-MET信号通路的靶向治疗将会对这些肿瘤有效。本文对近几年来HGF/c-MET信号通路的研究进展,包括该信号通路的基本信息、在相关肿瘤中的作用、临床治疗进展和遇到的困难以及相关对策进行综述。
以表皮生长因子受体(EGFR)、间变淋巴瘤激酶(ALK)基因融合变异等为治疗靶标的肺癌分子靶向治疗取得了长足进步。文章介绍了与EGFR酪氨酸激酶抑制剂(EGFR-TKI)和ALK基因融合变异抑制剂克唑替尼(Crizotinib)治疗用药相关的EGFR、K-RAS、BRAF、C-MET、EML4-ALK、ROS1等肺癌治疗靶向基因的作用原理,并详细阐述了上述基因分子病理检测的注意事项,包括对检测标本的要求、检测方法的选择和基因检测质量控制的要求。
在世界范围内,胃癌是发病率和死亡率非常高的恶性肿瘤,严重威胁着人类的健康。但是,胃癌的发病机制尚不完全清楚,目前认为其发生、发展是一个多因素、多步骤、复杂的渐进过程,涉及多条信号传导通路的异常改变。细胞间隙连接(gap

已经 junction intercellular communication,GJIC)是由相邻细胞间通过间隙连接所介导的一种通讯方式,参与
There is currently a split within the cancer research community between traditional molecular biological hypothesis-driven and the more recent “omic” forms or research. While the

molecular biological approach employs the tried and true single alteration-single response formulations of experimentation,the omic employs broad-based assay or sample collection approaches PARP抑制剂 that generate large volumes of data. How to integrate the benefits of these two approaches in an efficient and productive fashion remains an outstanding issue. Ideally,one would merge the understandability,exactness,simplicity,and testability of the molecular biological approach,with the larger amounts of data,simultaneous consideration of multiple alterations,consideration

of genes both of known interest along with the novel,cross-sample comparisons among cell lines and patient samples,and consideration of directed questions while simultaneously gaining exposure to the novel provided by the omic approach. While at the current time integration of the two disciplines remains problematic,attempts to do so are ongoing,and will be necessary for 无 the understanding of the large cell line screens including the Developmental Therapeutics Program’s NCI-60,the Broad Institute’s Cancer Cell Line Encyclopedia,and the Wellcome Trust Sanger Institute’s Cancer Genome Project,as well as the the Cancer Genome Atlas clinical samples project. Going forward there is significant benefit to be had from the integration of the molecular biological and the omic forms or research,with the desired goal being improved translational understanding and application.